$ARTV

$4.27 -$1.89 (30.68%) Close

$ARTV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 48.9M shares outstanding

Who owns ARTV?

By type of holder

Institutions 82.6% Insiders 17.4% Everyone else 0.0%

Concentration Top 10 holders own 191.1%

Rajeev Shah 37.7% · Peter Kolchinsky 37.7%

Institutional ownership

82.6%

+48.2 pts vs last qtr

Institutional holders

+32 vs last qtr

Net shares bought

+23.5M

by institutions in Q2 2026

New / sold out

39 / 7

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Ra Capital Management, L.P. +8.1M
Viking Global Investors LP NEW +2.6M

Biggest sellers in Q2 2026

venBio Partners LLC SOLD OUT −531.3K
Millennium Management LLC SOLD OUT −123.3K

Who is planning to sell?

Notices of proposed sale, last 12 months

$1.18M

11 notices from 7 people

Shares covered

140.7K

0.29% of the company

Arranged in advance

57%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Fred Aslan Director 10b5-1 $571K
Fred Aslan, M.D. Officer $258K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+2945.1%

+451.82% a year

Each share's claim on the business

−96.7%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $20.9M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years68% Under 1 year32%

Quarterly turnover

74.7%

of institutional shares changed hands

Top 10 managers, median time held

1.8 years

Super Investors

Investment managers reporting ARTV on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P. 13D · 37.9%	18.0M	36.73%	+8.1M (+82.2%)	2024	1.5%
Shares held by quarter Peak holding18.0M (Q2'26) Change over 8 quarters+8.1M Share of the company36.730% Disclosed stake13D · 37.9% Ra Capital Management, L.P.'s full portfolio →
VG Viking Global Investors LP	2.6M	5.33%	NEW	Q2 '26	0.1%
Shares held by quarter Peak holding2.6M (Q2'26) Change over 8 quarters+2.6M Share of the company5.330% Viking Global Investors LP's full portfolio →

Ra Capital Management, L.P.

13D · 37.9%

18.0M

% of company

36.73%

Change vs last qtr

+8.1M (+82.2%)

Held since

2024

Viking Global Investors LP

2.6M

% of company

5.33%

Change vs last qtr

NEW

Held since

Q2 '26

28 more super investors behind a free account

See every manager holding Artiva Biotherapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ARTV on Form N-PORT; together they hold 5.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$6.79M	699.9K	1.43%	0.00%	June 30, 2026
FB Franklin Biotechnology Discovery Fund Franklin Strategic Series	$5.48M	542.4K	1.11%	0.47%	July 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$6.79M

% of company

1.43%

% of the fund

0.00%

As of

June 30, 2026

Franklin Biotechnology Discovery Fund

Franklin Strategic Series

Position value

$5.48M

% of company

1.11%

% of the fund

0.47%

As of

July 31, 2026

23 more funds behind a free account

See every fund holding Artiva Biotherapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RS Rajeev Shah 5%+ holder 13D · 37.9%	18.4M	37.67%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company37.670% Disclosed stake13D · 37.9% View the 13D/G filing →
PK Peter Kolchinsky 5%+ holder 13D · 37.9%	18.4M	37.67%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company37.670% Disclosed stake13D · 37.9% View the 13D/G filing →

Rajeev Shah

5%+ holder13D · 37.9%

18.4M

% of company

37.67%

Change vs last qtr

—

Held since

—

Peter Kolchinsky

5%+ holder13D · 37.9%

18.4M

% of company

37.67%

Change vs last qtr

—

Held since

—

13 more holders behind a free account

See every insider and 5%+ holder of Artiva Biotherapeutics Inc.

Comments